Loss of wild‐type p53 not only dampens its tumor‐suppressive function but also obtains new oncogenic effects, called gain of function (GOF), such as enhanced capacity for metastasis, proliferation, and chemo‐resistance (Muller & Vousden, 2013), making the reactivation of wild‐type p53 or regulation of its downstream effectors' attractive therapeutic targets. Here, TP53 is linked to neoplasm.